Background: Prescribing potentially harmful drugs and omitting essential drugs to older patients is a common problem because they take so many medications. In this study, our goal was to identify potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) using Screening Tool of Older Persons' potentially inappropriate Prescriptions (STOPP) and Screening Tool to Alert doctors to the Right Treatment (START) criteria to improve proper prescription and reduce improper prescription.
INTRODUCTION
Aged patients have multiple diseases and so take many medications. There are many side effects of medication itself and drug-drug interactions, so physicians should consider these when they prescribe for elderly patients. Improved prescribing in the elderly tool (IPET) and Beers' criteria have been widely used as screening tools of inappropriate prescription to elderly patients, 1) but IPET does not contain many drugs frequently used for elderly patients, and Beers' criteria contains drugs not used in Korea.
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Some researchers found these tools were limited in discovering inappropriate prescription. 2, 3) O'Mahony and Gallagher 4) and Beers' criteria (Appendix 1). 3) In this study, we reviewed the diseases and medications of the elderly patients admitted to Inha University Hospital, and analyzed the prescriptions by applying the STOPP/START criteria.
METHODS

Study Population
Enrolled in this study were 117 patients 65 years or older admitted to any department in Inha University Hospital in 
Research Methods
We reviewed patients' sex, age, height, weight, past medical history, recent diagnosis, and medications they took before and after administration based on medical records. Regardless of formula, we reviewed all oral, intravenous and inhaled medications, and checked dosage and mode of use. We checked serum creatinine levels and calculated glomerular filtration rate.
Based on the information collected, we checked potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) by applying each item of the STOPP/START criteria to the patients. This report is a retrospective study based on medical records, and was approved by institutional review board of Inha University Hospital, and informed consent was waived.
Statistical Analysis
PASW SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical analysis.
RESULTS
Characteristics of Study Population
Of the 117 research subjects, 65 people were male (55%) and 52 were female (45%), with a mean age of 77.4 years. The most common age group was from 75 to 84, 58 persons (56%), Values are presented as number (%) or number. (Table 5) .
DISCUSSION
According to the National Health and Nutrition Examination Survey III, over half of patients between 65 to 74 years old take more than two medications, and 12% take over five. Over 75 years of age, more than 60% take two or more medications, and 16% take more than five medications. 5) A study conducted on 20,575 outpatients and 4,519 inpatients at one university hospital in Korea reported that outpatients were prescribed an average of six medications, and inpatients received 18. 6) Generally, elderly patients have multiple chronic diseases requiring a number of medications, and hospital admission will often more than double their usual amount. Therefore, physicians should pay close attention to medical history and current medication when adding a new medication for elderly patients.
In our study PIMs were found in 20.5% of patients according to the STOPP criteria. This is similar to the 21.4% in 1,329
elderly people who visited three general practices in Ireland.
2)
The fact that about one fifth of patients admitted to a university hospital where they are cared for by so many doctors and nurses have more than one inappropriate prescription is an important message to physicians.
Prescription for patients who had chronic constipation was the most common inappropriately prescribed medication, with 15 instances found in the current study. Possible explanations include that the physician ignored conditions such as constipation that could disturb the patient's quality of life, or the physician did not know that calcium channel blocker (CCB) could aggravate constipation, or that the patient has constipation. Another possible explanation is that though the physician knew it is possible that CCBs worsen constipation, important heart drugs could not be withheld.
One study that analyzed inappropriate drug prescriptions in elderly patients, using Beers' criteria intended for outpatients, found that of 20,575 people and the elderly of the 4,519 people admitted to a university hospital in 2004, 27.8% of patients Values are presented as number (%) or number. Gastrointestinal system
Gastroesophageal reflux disease and proton pump inhibitor 3 (6.5)
Total PPOs 46
received inappropriate medications. 6) That is higher than the percentage of 20.5 of this study, but lower than other studies 2) using the STOPP criteria. Perhaps because only hospitalized pneumonia patients are considered in this study, the percentage of inappropriate prescription may be lower than in other studies.
PPOs reviewed using the START criteria was 26.5%, slightly higher than the 22.7% in the Ireland study. This study has some limitations. First, it is impossible to generalize to the entire elderly population since this study was restricted to pneumonia patients admitted to a university hospital. Second, it is possible that there are omissions of patients' past medical history and medications, because we checked the patients' history and drugs only through the medical records created by the doctors or nurses.
However, this study is significant in that it is the first to describe the prescription of inappropriate drugs in elderly patients by using the STOPP/START criteria in Korea. In addition, while the role of previous tools was just to find inappropriate prescriptions, this study attempted to find potential prescription omissions using a new tool called START.
Analytic tools such as STOPP/START criteria are not the best way to find inappropriate prescription and potential omission for elderly patients. There might be many cases when a physician needs to use medication that nevertheless will be flagged as inappropriate. Prescription that meets each clinical situation is important, but if the physician understands these criteria and uses them properly, it should help minimize inappropriate prescriptions and reduce the side effects.
Hereafter, conducting a long term study using STOPP/ START criteria including not only the patients of a university hospital but also of a convalescent hospital and primary clinic is needed. We think there is a need to develop appropriate criteria to match the actual conditions in Korea.
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1) Cardiovascular system (1) Digoxin at a long-term dose > 125 μg/d with impaired renal function (estimated glomerular filtration rate [GFR] < 50 mL/min) (increased risk of toxicity) (2) Loop diuretic for dependent ankle edema only, i.e., no clinical signs of heart failure (no evidence of efficacy, compression hosiery usually more appropriate) (3) Loop diuretic as first-line monotherapy for hypertension (safer, more effective alternatives available) (4) Thiazide diuretic with a history of gout (may exacerbate gout) (5) Non-cardioselective beta-blocker with chronic obstructive pulmonary disease (COPD) (risk of bronchospasm) (6) Beta-blocker in combination with verapamil (risk of symptomatic heart block) (7) Use of diltiazem or verapamil with New York Heart Association class III or IV heart failure (may worsen heart failure) (8) Calcium channel blockers with chronic constipation (may exacerbate constipation) (9) Use of aspirin and warfarin in combination without histamine H 2 receptor antagonist (except cimetidine because of interaction with warfarin) or proton pump inhibitor (PPI, high risk of gastro-intestinal bleeding) (10) Dipyridamole as monotherapy for cardiovascular secondary prevention (no evidence for efficacy) (11) Aspirin with a past history of peptic ulcer disease without histamine H 2 receptor antagonist or PPI (risk of bleeding) (12) Aspirin at dose > 150 mg/d (increased bleeding risk, no evidence for increased efficacy) (13) Aspirin with no history of coronary, cerebral, or peripheral arterial symptoms or occlusive arterial event (not indicated) (14) Aspirin to treat dizziness not clearly attributable to cerebrovascular disease (not indicated) (15) Warfarin for first, uncomplicated deep venous thrombosis for longer than 6 months duration (no proven added benefit) (16) Warfarin for first uncomplicated pulmonary embolus for longer than 12 months duration (no proven benefit) (17) Aspirin, clopidogrel, dipyridamole, or warfarin with concurrent bleeding disorder (high risk of bleeding)
2) Central nervous system and psychotropic drugs (1) Tricyclic antidepressants (TCA's) with dementia (risk of worsening cognitive impairment) (2) TCA's with glaucoma (likely to exacerbate glaucoma) (3) TCA's with cardiac conductive abnormalities (pro-arrhythmic effects) (4) TCA's with constipation (likely to worsen constipation) (5) TCA's with an opiate or calcium channel blocker (risk of severe constipation) (6) TCA's with prostatism or prior history of urinary retention (risk of urinary retention) (7) Long-term (i.e., >1 mo), long-acting benzodiazepines, e.g., chlordiazepoxide, fluazepam, nitrazepam, chlorazepate, and benzodiazepines with long-acting metabolites, e.g., diazepam (risk of prolonged sedation, confusion, impaired balance, falls) (8) Long-term (i.e., >1 mo) neuroleptics as long-term hypnotics (risk of confusion, hypotension, extrapyramidal side effects, falls) (9) Long-term neuroleptics (>1 mo) in those with parkinsonism (likely to worsen extrapyramidal symptoms) (10) Phenothiazines in patients with epilepsy (may lower seizure threshold) (11) Anticholinergics to treat extrapyramidal side-effects of neuroleptic medications (risk of anticholinergic toxicity) (12) Selective serotonin re-uptake inhibitors (SSRI's) with a history of clinically significant hyponatraemia (non-iatrogenic hyponatraemia < 130 mmol/L within the previous 2 months) (13) Prolonged use (>1 wk) of first generation antihistamines, i.e., diphenydramine, chlorpheniramine, cyclizine, promethazine (risk of sedation and anticholinergic side effects)
3) Gastro-intestinal system (1) Diphenoxylate, loperamide, or codeine phosphate for treatment of diarrhoea of unknown cause (risk of delayed diagnosis, may exacerbate constipation with overflow diarrhoea, may precipitate toxic megacolon in inflammatory bowel disease, may delay recovery in unrecognised gastroenteritis) (2) Diphenoxylate, loperamide, or codeine phosphate for treatment of severe infective gastroenteritis, i.e., bloody diarrhoea, high fever or severe systemic toxicity (risk of exacerbation or protraction of infection) (3) Prochlorperazine (Stemetil) or metoclopramide with parkinsonism (risk of exacerbating parkinsonism) (4) PPI for peptic ulcer disease at full therapeutic dosage for > 8 weeks (earlier discontinuation or dose reduction for maintenance/ prophylactic treatment of peptic ulcer disease, esophagitis or gastroesophageal reflux disease indicated) (1) Metformin with type 2 diabetes ± metabolic syndrome in the absence of renal impairment (estimated GFR < 50 mL/min) (2) ACE inhibitor or angiotensin receptor blocker in diabetes with nephropathy, i.e., overt urinalysis proteinuria or micoralbuminuria (>30 mg/24 hours) ± serum biochemical renal impairment (estimated GFR < 50 mL/min) (3) Antiplatelet therapy in diabetes mellitus if one or more co-existing major cardiovascular risk factor present (hypertension, hypercholesterolaemia, smoking history) (4) Statin therapy in diabetes mellitus if one or more co-existing major cardiovascular risk factor present
